New hope for older AML patients: gentler chemo before transplant may boost survival
NCT ID NCT07598110
First seen May 23, 2026 · Last updated May 23, 2026
Summary
This study tests a milder chemotherapy combination (fludarabine and treosulfan) given before a stem cell transplant from a half-matched donor for older or frail adults with acute myeloid leukemia (AML). The goal is to see if this approach can help control the cancer longer while being easier on the body. About 77 participants aged 60-75 (or younger if too frail for standard chemo) will be enrolled. After the transplant, patients receive standard follow-up care and extra questionnaires.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.